

HIGH-DOSE BUPRENORPHINE: CLINICAL CONSIDERATIONS FACT SHEET

Background:

- Buprenorphine is an effective treatment for opioid use disorder (OUD). <u>Dosing guidance</u> has historically recommended a maximum daily dose of 24mg.
- A <u>2024 joint statement</u> from the FDA and SAMHSA has clarified that **24mg should** <u>not be</u> interpreted as a strict maximum, as some patients may benefit from higher doses.
 Increased fentanyl use has prompted some clinicians to opt for higher doses.
- Higher doses (≥24 mg) may be necessary to achieve the primary goals of <u>buprenorphine treatment</u>:
 - Suppress opioid withdrawal
 - Block the effects of illicit opioids
 - Reduce opioid craving and stop/reduce use of illicit opioids
 - Promote patient engagement in recovery-oriented activities

Patients taking higher doses (<u>>24mg</u>) of buprenorphine demonstrate:

- Better retention in treatment
- Lower <u>rates</u> of acute care utilization
- Decreased <u>mortality</u>



Clinical Considerations:

- Patient-Centered Dosing: Patients experiencing persistent withdrawal symptoms and continued opioid use might benefit from a buprenorphine dose to <a>24mg. For long-acting injectable buprenorphine formulations, continuing at the higher end of the dose range (e.g., Sublocade 300mg/month or Brixadi 128mg/month) is likely also to have clinical benefit.
- Harm Reduction Perspective: Higher doses may help stabilize patients in an environment where fentanyl is prevalent, reducing the likelihood of relapse and overdose.
- Safety:
 - <u>Overdose/Respiratory Depression</u>: A <u>recent literature review</u> found that high-dose buprenorphine initiation is **not** associated with increased overdose risk or respiratory depression. Overdose with buprenorphine in adults is not common and most likely <u>occurs</u> in individuals without tolerance or who use alcohol or benzodiazepines.
 - <u>Diversion</u>: Although diversion (unauthorized use of buprenorphine) remains a <u>concern</u>, the most common use of nonprescribed buprenorphine is <u>self-treatment</u> of OUD when <u>legal</u> <u>access</u> is unavailable. In the context of the fentanyl epidemic, buprenorphine misuse poses less risk than illicit opioid use. Patients should be educated on safe storage and misuse.

1-855-337-MACS (6227) | www.marylandmacs.org | macs@som.umaryland.edu